RegeneRx Biopharmaceuticals, Inc. announced that a new research paper was published demonstrating Thymosin Beta 4's (Tß4) positive effects on animal models related to Alzheimer's Disease. Researchers initially conducted behavior tests to assess learning, memory, anxiety and depression in mouse models expressing a human amyloid precursor protein and a mutant human presenilin 1, both of which are mutations associated with early-onset Alzheimer's Disease in humans. According to the researchers, among other findings, Tß4 over-expression in the mouse models alone showed less amyloid beta peptide, or amyloid deposits, which correlates with the clinical status of the patient. The research team also observed that over-expression of Tß4 improved neuronal function and cognitive behavior performance and displayed anti-depressant-like effects. In the study, Tß4 down regulated certain known inflammatory pathways, while other drug combinations did not, in particular NF-?B signaling.